Doan's FTC Correction Requirement Is "Punitive" And "Irrational" - Novartis
This article was originally published in The Tan Sheet
Executive Summary
Novartis is asking the Federal Trade Commission to stay the corrective advertising requirement in FTC's final order in the case regarding Doan's Pills advertising claims. The firm asserts FTC's requirement for corrective ad copy is punitive in nature and "irrational" in its application for a stay of Part IV of the commission's final order and decision. FTC had concluded certain superiority claims used in Doan's ads were deceptive.
You may also be interested in...
Novartis Appealing Doan's Pills FTC $8 Mil. Corrective Ad Order
Novartis plans to "file an appeal with a federal court" contesting the Federal Trade Commission's May 27 order requiring corrective advertising and labeling for Doan's Pills ad claims. In a 4-0 vote, the commission reversed a March 1998 administrative law judge's decision not to impose corrective advertising to remedy what FTC charges were deceptive superiority claims.
Novartis Doan's back pain relief superiority claims not supported, FTC judge concludes.
NOVARTIS DOAN'S BACK PAIN RELIEF SUPERIORITY CLAIMS NOT SUPPORTED, FTC Administrative Law Judge Lewis Parker said in a March 9 decision and order upholding charges made by the Federal Trade Commission. Novartis is prohibited from claiming Doan's "is more effective than other over-the-counter analgesic drugs for relieving back pain or any other particular kind of pain, unless, at the time of making such representation, respondents possess and rely upon competent and reliable scientific evidence that substantiates the representation," the order states.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC